Current Status of Heart Transplantation and Left Ventricular Assist Device: Major Changes in the Last Decade.
10.7599/hmr.2014.34.4.185
- Author:
Sook Jin LEE
1
;
Suk Geun HONG
Author Information
1. Division of Cardiology, Department of Internal Medicine, Sejong General Hospital, Bucheon, Korea. skjnlee@gmail.com
- Publication Type:Review
- Keywords:
Heart Transplantation;
Heart-Assist Devices;
Graft Rejection
- MeSH:
Allergy and Immunology;
Antibodies;
Antibody Formation;
Biopsy;
Classification;
Diagnosis;
Graft Rejection;
Heart;
Heart Failure;
Heart Transplantation*;
Heart-Assist Devices*;
HLA Antigens;
Humans;
Immunotherapy;
Leukocytes;
Mortality;
Sensitivity and Specificity;
Survival Rate;
Tissue Donors;
Waiting Lists
- From:Hanyang Medical Reviews
2014;34(4):185-196
- CountryRepublic of Korea
- Language:English
-
Abstract:
Heart transplantation is the last treatment option in refractory end stage heart failure, which can prolong survival. The number of heart transplantations has increased and the survival rate has improved during the last few decades which was contributed by advanced understanding of immunologic mechanism of rejection, pharmaceutical development and clinical management of donors and recipients. However, only a fraction of patients can be offered to transplantation due to shortage of donor heart and many patients suffer high mortality while waiting. Meanwhile, technical advancement of mechanical assist device in recent years enabled long term implantable left ventricular assist devices (LVAD) to bridge the patients with high mortality in the waiting list to transplantation and to assist as a long term destination therapy for patients who are not eligible for transplantation. Development of solid phase assay increased the sensitivity and the specificity of detection of anti-human leukocyte antigen (HLA) antibodies in the recipient. It enabled identifying unacceptable HLA antigens, acquire calculated Panel Reactive Antibodies and perform virtual cross match that can enhance the efficacy of donor allocation system to decrease the waiting time, obviate prospective cross match to decrease ischemic time and to assess the risk of rejection in presensitized patients. Antibody mediated rejection is a challenging entity in diagnosis and management. However, standardized classification of histology and immunology of endomyocardial biopsies was made recently and immunotherapy is moving toward targeted therapies directed at antibody production and function. This review focuses on those major changes in the heart transplantation field in the last decade.
